Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/21914
Ficheiros no ítem
Metadatos do ítem
Título: | Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron |
Autor/a: | Allahham, Nour Fina, Fabrizio Marcuta, Carmen Kraschew, Lilia Mohr, Wolfgang Gaisford, Simon Basit, Abdul W. Goyanes Goyanes, Álvaro |
Centro/Departamento: | Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica |
Palabras chave: | Three-Dimensional Printing | 3D Printed Drug Products | Printing Pharmaceuticals | Additive Manufacturing | Rapid Prototyping | Orally Disintegrating Tablets (Odts) | Orally Disintegrating Printlets (Odps) | Taste Masking | Personalized Medicines | |
Data: | 2020 |
Editor: | MDPI |
Cita bibliográfica: | Allahham, N.; Fina, F.; Marcuta, C.; Kraschew, L.; Mohr, W.; Gaisford, S.; Basit, A.W.; Goyanes, A. Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron. Pharmaceutics 2020, 12, 110 |
Resumo: | The aim of this work was to explore the feasibility of using selective laser sintering (SLS) 3D printing (3DP) to fabricate orodispersable printlets (ODPs) containing ondansetron. Ondansetron was first incorporated into drug-cyclodextrin complexes and then combined with the filler mannitol. Two 3D printed formulations with different levels of mannitol were prepared and tested, and a commercial ondansetron orally disintegrating tablet (ODT) product (Vonau® Flash) was also investigated for comparison. Both 3D printed formulations disintegrated at ~15 s and released more than 90% of the drug within 5 min independent of the mannitol content; these results were comparable to those obtained with the commercial product. This work demonstrates the potential of SLS 3DP to fabricate orodispersible printlets with characteristics similar to a commercial ODT, but with the added benefit of using a manufacturing technology able to prepare medicines individualized to the patient. |
Versión do editor: | https://doi.org/10.3390/pharmaceutics12020110 |
URI: | http://hdl.handle.net/10347/21914 |
DOI: | 10.3390/pharmaceutics12020110 |
E-ISSN: | 1999-4923 |
Dereitos: | © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) |
Coleccións
-
- FTF-Artigos [274]